Evolent Health Statistics
Total Valuation
Evolent Health has a market cap or net worth of $796.72 million. The enterprise value is $1.51 billion.
Important Dates
The next confirmed earnings date is Thursday, November 6, 2025, after market close.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Evolent Health has 115.97 million shares outstanding. The number of shares has increased by 1.40% in one year.
| Current Share Class | 115.97M |
| Shares Outstanding | 115.97M |
| Shares Change (YoY) | +1.40% |
| Shares Change (QoQ) | +0.49% |
| Owned by Insiders (%) | 1.68% |
| Owned by Institutions (%) | 91.04% |
| Float | 91.32M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 13.37 |
| PS Ratio | 0.37 |
| Forward PS | 0.38 |
| PB Ratio | 0.92 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.69 |
| EV / EBITDA | 20.88 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.01, with a Debt / Equity ratio of 0.76.
| Current Ratio | 1.01 |
| Quick Ratio | 0.91 |
| Debt / Equity | 0.76 |
| Debt / EBITDA | 10.95 |
| Debt / FCF | n/a |
| Interest Coverage | -0.24 |
Financial Efficiency
Return on equity (ROE) is -11.04% and return on invested capital (ROIC) is -0.27%.
| Return on Equity (ROE) | -11.04% |
| Return on Assets (ROA) | -0.21% |
| Return on Invested Capital (ROIC) | -0.27% |
| Return on Capital Employed (ROCE) | -0.44% |
| Revenue Per Employee | $487,982 |
| Profits Per Employee | -$41,152 |
| Employee Count | 4,500 |
| Asset Turnover | 0.89 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -1.10M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -70.26% in the last 52 weeks. The beta is 0.66, so Evolent Health's price volatility has been lower than the market average.
| Beta (5Y) | 0.66 |
| 52-Week Price Change | -70.26% |
| 50-Day Moving Average | 8.56 |
| 200-Day Moving Average | 9.36 |
| Relative Strength Index (RSI) | 33.87 |
| Average Volume (20 Days) | 2,180,659 |
Short Selling Information
The latest short interest is 17.62 million, so 15.19% of the outstanding shares have been sold short.
| Short Interest | 17.62M |
| Short Previous Month | 23.10M |
| Short % of Shares Out | 15.19% |
| Short % of Float | 19.30% |
| Short Ratio (days to cover) | 5.61 |
Income Statement
In the last 12 months, Evolent Health had revenue of $2.20 billion and -$185.19 million in losses. Loss per share was -$1.61.
| Revenue | 2.20B |
| Gross Profit | 359.26M |
| Operating Income | -8.35M |
| Pretax Income | -131.55M |
| Net Income | -185.19M |
| EBITDA | 72.25M |
| EBIT | -8.35M |
| Loss Per Share | -$1.61 |
Full Income StatementBalance Sheet
The company has $151.00 million in cash and $853.19 million in debt, giving a net cash position of -$702.20 million or -$6.05 per share.
| Cash & Cash Equivalents | 151.00M |
| Total Debt | 853.19M |
| Net Cash | -702.20M |
| Net Cash Per Share | -$6.05 |
| Equity (Book Value) | 1.12B |
| Book Value Per Share | 7.73 |
| Working Capital | 4.74M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$33.33 million and capital expenditures -$88.13 million, giving a free cash flow of -$121.46 million.
| Operating Cash Flow | -33.33M |
| Capital Expenditures | -88.13M |
| Free Cash Flow | -121.46M |
| FCF Per Share | -$1.05 |
Full Cash Flow StatementMargins
Gross margin is 16.36%, with operating and profit margins of -0.38% and -5.94%.
| Gross Margin | 16.36% |
| Operating Margin | -0.38% |
| Pretax Margin | -5.99% |
| Profit Margin | -5.94% |
| EBITDA Margin | 3.29% |
| EBIT Margin | -0.38% |
| FCF Margin | n/a |
Dividends & Yields
Evolent Health does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.40% |
| Shareholder Yield | -1.40% |
| Earnings Yield | -22.98% |
| FCF Yield | -15.07% |
Dividend DetailsAnalyst Forecast
The average price target for Evolent Health is $15.79, which is 129.84% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $15.79 |
| Price Target Difference | 129.84% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (5Y) | 7.60% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Evolent Health has an Altman Z-Score of 1.21 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.21 |
| Piotroski F-Score | 1 |
